Election of Executives at the Fourth Annual (2024FY) General Shareholders Meeting

We are pleased to announce that the following officers were elected at our company's Fourth Annual (2024FY) General Shareholders Meeting and have officially assumed their respective positions. To strengthen our management structure, Kosuke Matsunaga has been appointed as Representative Director, effective immediately.

Moving forward, our executive team remains committed to the advancement of innovative cancer treatments. We sincerely appreciate your continued support.

Newly Elected and Continuing Board Members:

• President & CEO: Kosuke Matsunaga (New Appointment)

• Chairman of the Board: Kazuto Takesako (Continuing)

• Senior Vice President, COO: Masanobu Kimura (Continuing)

• Director (Outside): Kei Fujioka (Continuing, Representative Director of Takt Pharma Co., Ltd.)

• Auditor: Takashi Mitsuguchi (New Appointment, DBJ Capital)

Kosuke Matsunaga was born in 1981 and graduated from the University of Massachusetts. He has an extensive background in the pharmaceutical industry, with experience at leading companies:

• 2007: ABsize

• 2012: Takeda Pharmaceutical

• 2020: AbbVie

• 2022: Reborna Biosciences

With this new leadership structure, we are confident in our ability to drive the company’s growth and contribute to the development of groundbreaking treatments.

Thank you for your continued trust and support.

γδT Cell Project Adopted as Research and Development Support Program for Growth-Type Small and Medium Sized Enterprises (GO-TECH)

One of our programs, γδT cell project, was adopted as Research and Development

Support Program for Growth-Type Small and Medium Sized Enterprises (GO-TECH) 2024 by Small and Medium Enterprise Agency on June 24, and it was on the web on the same day（https://www.chubu.meti.go.jp/b31technology/sapoin/kouhyou/2024fy/saitakuitiran.pdf）. The title is “Mass Manufacturing Technology Development of Ready-Made Type γδ T Cells with Ultra-High Purity”.

（About γδT Cell）

Among human peripheral T cells, γδ T cells express unique T cell receptor (TCR)

composed with one γchain and one δ chain. Most human peripheral T cells express a TCR composed withα and β glycoprotein chains, and the ratio of γδ T cells is 1-5%. αβ T cells cause graft-versus-host disease (GVHD) while allogenic transplantation, recognizing the recipient as others and causing immune-response. It is known that ɤδ T cells are HLA independent and would not cause GVHD, and suitable for Ready-Made T cell therapy.

AMED Adopted GD2 GITRL CAR Project as Strengthening Program for the Pharmaceutical Startup Ecosystem Initiative

One of our programs, GD2 GITRL CAR project, was adopted as Strengthening Program for the Pharmaceutical Startup Ecosystem Initiative 2024 by Japan Agency for Medical Research and Development (AMED) on June 14, and it was on the web on the same day (https://www.amed.go.jp/koubo/19/02/1902C_00047.html).  The title is “Research and Development of a Novel CAR-T Therapy, incorporating GITRL, on GD2 Positive Refractory Solid Tumors”.  

(Reference)

About GD2:

GD2 is a glycolipid predominantly expressed on the surface of nerve cells, confirmed to be excessively expressed in various cancers, including neuroblastoma, a type of pediatric cancer, as well as triple negative breast cancer and melanoma.